Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette

Slides:

Advertisements

Similar presentations

Minimally invasive treatment of varicose veins: Endovenous laser ablation (EVLA) Georgios Galanopoulos, Constantinos Lambidis International Journal of.

Advertisements

Volume 42, Issue 1, Pages 7-11 (July 2002)

Medical Management for BPH: The Role of Combination Therapy

Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review,

Pascal Rischmann European Urology Supplements

PD26-05 A RANDOMIZED TRIAL COMPARING GREENLIGHT (XPS) LASER PHOTOSELECTIVE VAPO-ENUCLEATION OF THE PROSTATE (PVEP) VERSUS HOLMIUM LASER ENUCLEATION OF.

Volume 43, Issue 5, Pages (May 2003)

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Management of Acute and Chronic Retention in Men

Volume 64, Issue 1, Pages (July 2013)

Volume 191, Issue 1, Pages (January 2014)

Volume 61, Issue 6, Pages (June 2012)

Olivier Traxer European Urology Supplements

Volume 52, Issue 2, Pages (August 2007)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Rowland Illing European Urology Supplements

Volume 64, Issue 3, Pages (September 2013)

Volume 43, Issue 5, Pages (May 2003)

Volume 53, Issue 2, Pages (February 2008)

Cholinergic Innervation and Muscarinic Receptors in the Human Prostate

Volume 55, Issue 2, Pages (February 2009)

Volume 44, Issue 1, Pages (July 2003)

Volume 46, Issue 4, Pages (October 2004)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Back to the Future: Introduction and Conclusions

Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Raymond C. Rosen, Francois Giuliano, Culley.

Volume 52, Issue 3, Pages (September 2007)

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Rowland Illing European Urology Supplements

Volume 58, Issue 3, Pages (September 2010)

Volume 60, Issue 4, Pages (October 2011)

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Volume 61, Issue 3, Pages (March 2012)

Counselling the Prostate Cancer Patient

Volume 68, Issue 4, Pages (October 2015)

Yuanshan Cui, Yong Zhang European Urology

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

Volume 65, Issue 5, Pages (May 2014)

Richard C. Harkaway European Urology Supplements

Volume 54, Issue 2, Pages (August 2008)

Training in Percutaneous Nephrolithotomy—A Critical Review

Tim Schneider European Urology Supplements

Transurethral Resection of the Prostate

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Volume 54, Issue 6, Pages (December 2008)

Volume 52, Issue 6, Pages (December 2007)

When to Treat the Prostate, the Bladder, or Both?

How and When to Take Prostate Biopsies

Jean J.M.C.H. de la Rosette, Vladimir Mouraviev, Thomas J. Polascik

Volume 53, Issue 6, Pages (June 2008)

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? François Desgrandchamps European Urology.

Christian Stief European Urology Supplements

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Emmanuel Chartier-Kastler, Kate Davidson European Urology Supplements

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Martin Michel, Jean de la Rosette European Urology Supplements

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Improving Flexibility and Quality of Life for Your Patients: A Must?

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

C.G Roehrborn, T McNicholas European Urology Supplements

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Michael Marberger European Urology Supplements

Introduction European Urology Supplements

Presentation transcript:

Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette European Urology Supplements Volume 8, Issue 6, Pages 513-522 (April 2009) DOI: 10.1016/j.eursup.2009.02.004 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Comparative display of the position of transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), holmium laser enucleation of the prostate (HoLEP), and potassium titanyl phosphate (KTP) laser based on the International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax) weighted mean differences (WMDs) between each minimally invasive surgical technique and transurethral resection of the prostate as estimated by meta-analyses (except KTP, only one randomised controlled trial). European Urology Supplements 2009 8, 513-522DOI: (10.1016/j.eursup.2009.02.004) Copyright © 2009 European Association of Urology Terms and Conditions